Mefenorex

Jump to: navigation, search
This image is provided by the National Library of Medicine.

WikiDoc Resources for Mefenorex

Articles

Most recent articles on Mefenorex

Most cited articles on Mefenorex

Review articles on Mefenorex

Articles on Mefenorex in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Mefenorex

Images of Mefenorex

Photos of Mefenorex

Podcasts & MP3s on Mefenorex

Videos on Mefenorex

Evidence Based Medicine

Cochrane Collaboration on Mefenorex

Bandolier on Mefenorex

TRIP on Mefenorex

Clinical Trials

Ongoing Trials on Mefenorex at Clinical Trials.gov

Trial results on Mefenorex

Clinical Trials on Mefenorex at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Mefenorex

NICE Guidance on Mefenorex

NHS PRODIGY Guidance

FDA on Mefenorex

CDC on Mefenorex

Books

Books on Mefenorex

News

Mefenorex in the news

Be alerted to news on Mefenorex

News trends on Mefenorex

Commentary

Blogs on Mefenorex

Definitions

Definitions of Mefenorex

Patient Resources / Community

Patient resources on Mefenorex

Discussion groups on Mefenorex

Patient Handouts on Mefenorex

Directions to Hospitals Treating Mefenorex

Risk calculators and risk factors for Mefenorex

Healthcare Provider Resources

Symptoms of Mefenorex

Causes & Risk Factors for Mefenorex

Diagnostic studies for Mefenorex

Treatment of Mefenorex

Continuing Medical Education (CME)

CME Programs on Mefenorex

International

Mefenorex en Espanol

Mefenorex en Francais

Business

Mefenorex in the Marketplace

Patents on Mefenorex

Experimental / Informatics

List of terms related to Mefenorex

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Mefenorex (Rondimen, Pondinil, Anexate) is a stimulant drug which was used as an appetite suppressant. It is an amphetamine derivative which was developed in the 1970s and used for the treatment of obesity.[1][2] Mefenorex produces amphetamine as a metabolite,[3] and has been withdrawn in many countries despite having only mild stimulant effects and relatively little abuse potential.[4]

References

  1. Vincendeau MJ. A new regulator of appetite: mefenorex. (French). Bordeaux Medical. 1970 Jul-Aug;3(7):1951-3.
  2. Beyer G, Huth K, Muller GM, Niemoller H, Raisp I, Vorberg G. The treatment of obesity with the appetite curbing agent Mefenorex. (German). Die Medizinische Welt. 1980 Feb;31(8):306-9.
  3. Rendic S, Slavica M, Medic-Saric M. Urinary excretion and metabolism of orally administered mefenorex. European Journal of Drug Metabolism and Pharmacokinetics. 1994 Apr-Jun;19(2):107-17.
  4. Engel J, Kristen G, Schaefer A, von Schlichtegroll A. Mefenorex (Rondimen). Drug and Alcohol Dependence. 1986 Jun;17(2-3):229-34.

Linked-in.jpg